Protagonist Therapeutics (PTGX) IPO Opened Flat
Get Alerts PTGX Hot Sheet
Join SI Premium – FREE
Today's IPO for Protagonist Therapeutics (NASDAQ: PTGX) opened for trading earlier at $12 after pricing 7,500,000 shares of common stock at a price to the public of $12 per share, the middle of the expected $11 - $13 range.
Leerink Partners LLC, Barclays Capital Inc. and BMO Capital Markets Corp. are acting as joint book-running managers for the offering.
Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rubrik, Inc. (RBRK) IPO Opens at $38.60, Priced at $32
- Neo-Concept International Group Holdings (NCI) Prices 2.32M Share IPO at $4/sh
- Rectitude Holdings (RECT) Announces 2M Share IPO at $4-$6/sh
Create E-mail Alert Related Categories
IPOsRelated Entities
BMO Capital, Barclays, IPOSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!